GoAI
Get started
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$96.31

−$0.76 · -0.78%

Aug 21, 4:00 PM ET

MIRM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

65

Undervalued

Momentum

71

Gaining

Sentiment

62

Bullish

Risk resilience

68

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Christopher Peetz
Listed since
Jul 18, 2019
Employees
433

Market position

Day range

Current $96.31

52-week range

Current $96.31

Open
$96.84
Previous close
$97.07
Volume
731.68K
0.82× average
Average volume
897.67K
Average daily volume
Market cap
5.87B USD
Beta
0.51
Market reference 1
50-day average
$110.53
-12.87% below average
200-day average
$94.6284
+1.78% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.99B USD
P/E (TTM)
-6.62×
P/B (TTM)
-585.64×
P/S (TTM)
9.5×
EV / EBITDA
231.78×
Earnings yield
-0.59%
Free cash flow yield
1.38%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
81.70%
Operating margin
-17.42%
Net margin
-139.18%
Return on equity
-7.42%
Return on assets
-2.77%
Return on invested capital
-3.46%

Financial health

Debt / equity
-72.97×
Current ratio
2.67×
Altman Z-score
-0.17
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends190%-209%-607%-1006%Gross margin, FY2021: 90.06%Gross margin, FY2022: 83.94%Gross margin, FY2023: 74.76%Gross margin, FY2024: 75.77%Gross margin, FY2025: 80.71%Operating margin, FY2021: -906.12%Operating margin, FY2022: -170.28%Operating margin, FY2023: -58.57%Operating margin, FY2024: -26.00%Operating margin, FY2025: -4.25%Net margin, FY2021: -438.85%Net margin, FY2022: -176.05%Net margin, FY2023: -87.68%Net margin, FY2024: -26.10%Net margin, FY2025: -4.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 90.06%. Gross margin FY2022 83.94%. Gross margin FY2023 74.76%. Gross margin FY2024 75.77%. Gross margin FY2025 80.71%. Operating margin FY2021 -906.12%. Operating margin FY2022 -170.28%. Operating margin FY2023 -58.57%. Operating margin FY2024 -26.00%. Operating margin FY2025 -4.25%. Net margin FY2021 -438.85%. Net margin FY2022 -176.05%. Net margin FY2023 -87.68%. Net margin FY2024 -26.10%. Net margin FY2025 -4.48%.

Income trends

Revenue

521.31M USD+54.74%

Operating income

−22.14M USD+74.73%

Net income

−23.36M USD+73.43%
Income trends across reported periods590.78M USD312.89M USD35M USD−242.89M USDRevenue, FY2021: 19.14M USDRevenue, FY2022: 77.06M USDRevenue, FY2023: 186.37M USDRevenue, FY2024: 336.89M USDRevenue, FY2025: 521.31M USDOperating income, FY2021: −173.41M USDOperating income, FY2022: −131.22M USDOperating income, FY2023: −109.15M USDOperating income, FY2024: −87.61M USDOperating income, FY2025: −22.14M USDNet income, FY2021: −83.99M USDNet income, FY2022: −135.67M USDNet income, FY2023: −163.42M USDNet income, FY2024: −87.94M USDNet income, FY2025: −23.36M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 19.14M USD. Revenue FY2022 77.06M USD. Revenue FY2023 186.37M USD. Revenue FY2024 336.89M USD. Revenue FY2025 521.31M USD. Operating income FY2021 −173.41M USD. Operating income FY2022 −131.22M USD. Operating income FY2023 −109.15M USD. Operating income FY2024 −87.61M USD. Operating income FY2025 −22.14M USD. Net income FY2021 −83.99M USD. Net income FY2022 −135.67M USD. Net income FY2023 −163.42M USD. Net income FY2024 −87.94M USD. Net income FY2025 −23.36M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue521.31M USD336.89M USD186.37M USD77.06M USD19.14M USD
Cost of goods sold100.58M USD81.64M USD47.04M USD12.37M USD1.9M USD
Gross profit420.73M USD255.25M USD139.34M USD64.69M USD17.24M USD
Research and development186.18M USD140.63M USD102.61M USD106.84M USD131.43M USD
Selling, general, and administrative257.03M USD202.22M USD145.88M USD89.07M USD59.22M USD
Operating expenses443.21M USD342.85M USD248.49M USD195.91M USD190.65M USD
Interest income12.73M USD13.79M USD13.74M USD3.86M USD366K USD
Interest expense14.39M USD14.31M USD15.11M USD15.98M USD17.59M USD
Depreciation and amortization24.24M USD23.63M USD10.83M USD3.24M USD975K USD
Operating income−22.14M USD−87.61M USD−109.15M USD−131.22M USD−173.41M USD
Net income−23.36M USD−87.94M USD−163.42M USD−135.67M USD−83.99M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-354.68%
11 comparable reports
Latest EPS result
-1.06
Estimate -0.74 · Miss by 42.75%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.13-4.08-9.3-14.51Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.49, estimate -0.27, surprise -81.48%, Miss. Q2 2025, reported May 7, 2025: actual -0.3, estimate -0.39, surprise +23.08%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.12, estimate -0.31, surprise +61.29%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.05, estimate -0.1, surprise +150.00%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.11, estimate 0.02, surprise -650.00%, Miss. Q2 2026, reported May 6, 2026: actual -13.43, estimate -0.4, surprise -3257.50%, Miss. Q3 2026, reported Aug 5, 2026: actual -1.06, estimate -0.743, surprise -42.75%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.526, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates185.18M153.3M121.41M89.52MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 99.41M USD, estimate 96.64M USD, surprise +2.87%, Beat. Q2 2025, reported May 7, 2025: actual 111.59M USD, estimate 98.4M USD, surprise +13.40%, Beat. Q3 2025, reported Aug 6, 2025: actual 127.79M USD, estimate 130.11M USD, surprise -1.79%, Miss. Q4 2025, reported Nov 4, 2025: actual 133.01M USD, estimate 140.88M USD, surprise -5.59%, Miss. Q1 2026, reported Feb 25, 2026: actual 148.93M USD, estimate 142.5M USD, surprise +4.51%, Beat. Q2 2026, reported May 6, 2026: actual 159.9M USD, estimate 148.21M USD, surprise +7.89%, Beat. Q3 2026, reported Aug 5, 2026: actual 176.2M USD, estimate 166.33M USD, surprise +5.93%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 178.06M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$138.3

43.60% upside
Past 12 months12-month forecastHigh $165Average $138.3Low $118

Rating distribution

18 ratings
Strong buy16%
Buy1794%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions

MIRM news

businesswire.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Read source
zacks.com

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Read source
seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Mirum Pharmaceuticals Q2 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical…

Read source
zacks.com

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and…

Read source
zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.

Read source

MIRM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MIRM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
175.29M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
126.27M
Weight
0.07%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
117.36M
Weight
0.15%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
107.75M
Weight
0.95%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
73.07M
Weight
0.16%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
58.78M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
42.85M
Weight
0.29%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
35.96M
Weight
0.34%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%

Continue in GoAI

Research MIRM

research.disclaimer